ADAR1's 7.4% Inovio Holding Includes Shares Underlying Warrants
The investment adviser's reported position combines common shares in managed funds and accounts with shares underlying fund-held warrants.
ADAR1 Capital Management, an investment adviser, reported a 7.4% holding in Inovio Pharmaceuticals, which develops DNA medicines, including shares underlying warrants. Its passive ownership disclosure filed Monday covers the position as of June 30, 2026.
Warrants Account For The Larger Component
ADAR1 reported beneficial ownership of 6,429,624 shares. The total includes 4,285,714 shares underlying warrants held by its private investment funds, alongside 2,143,910 common shares owned by managed funds and separately managed accounts.
The warrants give their holders rights to obtain common shares. The reported ownership figure therefore includes both common shares already held and shares underlying those instruments.
ADAR1 based its percentage on 82,341,945 outstanding shares at June 30, 2026. That share count came from Inovio's second-quarter report, filed August 12, 2026.
Schneeberger Reports The Same Securities
Daniel Schneeberger, ADAR1's sole manager, reported the same 6,429,624 shares and 7.4% beneficial ownership through his control of the adviser. His reported position covers the same securities attributed to ADAR1.
Both reporting persons listed shared voting power over the reported securities. They certified that the securities were bought and held as part of ordinary business, without an aim or effect of changing or influencing Inovio's control.
DNA Medicines Still In Development
Inovio is a clinical-stage biotechnology company developing treatments for diseases associated with human papillomavirus, cancer and infectious diseases. Its lead candidate, INO-3107, targets recurrent respiratory papillomatosis, a rare condition that produces airway tumors.
The medicines rely on small, circular DNA molecules called plasmids to tell cells to produce particular proteins. Inovio's CELLECTRA devices use short electrical pulses to deliver the medicines into cells.
Other candidates target throat cancer and additional cancers. In its annual report for 2025, Inovio said its DNA medicines had been administered more than 19,000 times to nearly 6,000 participants.
All of Inovio's candidates remain in research and development. Its revenue comes from licensing, milestone payments and collaborative research agreements and contracts; it has not earned revenue from product sales.